Pharmacological considerations of primary alkylators.
McCune
Jeannine S
JS
Department of Clinical Research, Fred Hutchinson Cancer Rsearch Center, Seattle, Washington, USA.
Slattery
John T
JT
D000970:Antineoplastic Agents / Q000493:pharmacokinetics; D018906:Antineoplastic Agents, Alkylating / Q000493:pharmacokinetics*; D002066:Busulfan / Q000493:pharmacokinetics*; D016190:Carboplatin / Q000493:pharmacokinetics; D002330:Carmustine / Q000493:pharmacokinetics; D002945:Cisplatin / Q000493:pharmacokinetics; D003520:Cyclophosphamide / Q000493:pharmacokinetics*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007069:Ifosfamide / Q000493:pharmacokinetics; D013852:Thiotepa / Q000493:pharmacokinetics
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; D013852:Thiotepa; D016190:Carboplatin; D002066:Busulfan; D002945:Cisplatin; D002330:Carmustine; D007069:Ifosfamide